+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chemotherapy Induced Neutropenia Market by Type of Drug, Treatment Type, Route of Administration, End-Use - Global Forecast 2025-2030- Product Image
Chemotherapy Induced Neutropenia Market by Type of Drug, Treatment Type, Route of Administration, End-Use - Global Forecast 2025-2030- Product Image
Sale

Chemotherapy Induced Neutropenia Market by Type of Drug, Treatment Type, Route of Administration, End-Use - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011313
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chemotherapy Induced Neutropenia Market grew from USD 7.39 billion in 2023 to USD 7.77 billion in 2024. It is expected to continue growing at a CAGR of 4.21%, reaching USD 9.87 billion by 2030.

Chemotherapy Induced Neutropenia (CIN) is a significant complication encountered in cancer treatment, characterized by an abnormally low level of neutrophils, which are crucial white blood cells for combating infection. The resulting vulnerability necessitates effective management strategies to mitigate infections and maintain chemotherapy efficacy. The application of Colony Stimulating Factors (CSFs), particularly Granulocyte Colony Stimulating Factor (G-CSF), is pivotal in preventing and treating CIN, thus improving patient outcomes and enabling adherence to clinical oncology regimens. The primary end-users of these solutions include hospitals, oncology centers, and research institutes globally. Market growth is propelled by the increasing prevalence of cancer, expanding oncology drug pipeline, and rising geriatric population, which collectively fuel the demand for CIN interventions. Emerging opportunities lie in the development of novel therapeutics and biosimilars aimed at enhancing PSF cost-effectiveness and accessibility. Precision medicine and personalized treatment regimens represent innovative domains holding substantial promise for tailored CIN management. Nevertheless, market constraints include the high cost of treatments, potential side effects associated with CSF use, and inconsistent reimbursement policies, which impede optimal market penetration. Additionally, the evolving landscape due to generic substitutes and biosimilars impacts market dynamics. In response, companies should invest in research to innovate less expensive, equally effective treatment options, alongside initiatives for improved policy reimbursement frameworks. Furthermore, tapping into technological advancements such as digital health platforms, which enable remote monitoring of neutrophil levels, can transform patient management paradigms. Organizations should also prioritize strategic collaborations with biotech firms to scale innovation and bring novel solutions to the market swiftly. Despite existing hurdles, the market for chemotherapy-induced neutropenia solutions remains promising for stakeholders committed to driving forward-looking, patient-centric innovations.

Understanding Market Dynamics in the Chemotherapy Induced Neutropenia Market

The Chemotherapy Induced Neutropenia Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of cancer leading to higher chemotherapy usage and subsequent rise in cases of induced neutropenia
    • Growing awareness and early diagnosis of chemotherapy-induced neutropenia enhancing patient management strategies
    • Advancements in supportive care therapies and growth factors to effectively mitigate neutropenia risks
    • Government and healthcare initiatives promoting research and development of novel treatments for chemotherapy-induced neutropenia
  • Market Restraints
    • Lack of awareness and education among patients and healthcare providers regarding neutropenia risks and treatment options in chemotherapy
    • High treatment costs and limited reimbursement options hindering patient access to chemotherapy induced neutropenia therapies
  • Market Opportunities
    • Innovative combination therapies integrating immunotherapy and g-csf in chemotherapy induced neutropenia management
    • Personalized medicine approaches using genetic screening to tailor treatments for neutropenia caused by chemotherapy
    • Expansion of telehealth services for remote monitoring and management of neutropenic patients undergoing chemotherapy
  • Market Challenges
    • Economic and healthcare policy challenges impacting chemotherapy induced neutropenia market dynamics
    • Technological and infrastructure limitations hindering advancements in chemotherapy induced neutropenia management

Exploring Porter’s Five Forces for the Chemotherapy Induced Neutropenia Market

Porter’s Five Forces framework further strengthens the insights of the Chemotherapy Induced Neutropenia Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Chemotherapy Induced Neutropenia Market

External macro-environmental factors deeply influence the performance of the Chemotherapy Induced Neutropenia Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Chemotherapy Induced Neutropenia Market

The Chemotherapy Induced Neutropenia Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Chemotherapy Induced Neutropenia Market

The Chemotherapy Induced Neutropenia Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Chemotherapy Induced Neutropenia Market

The Chemotherapy Induced Neutropenia Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chemotherapy Induced Neutropenia Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Apotex Inc., Baxter International Inc., BeyondSpring Pharmaceuticals, Biogen Inc., Coherus BioSciences, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, G1 Therapeutics, Hoffmann-La Roche Ltd., Kiadis Pharma, Mylan N.V., Novartis AG, OncoGenerix USA Inc., Pfizer Inc., Sandoz International GmbH, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Chemotherapy Induced Neutropenia Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type of Drug
    • Antibiotics
    • Antifungals
    • Antivirals
    • Colony Stimulating Factor
      • Filgrastim
      • Lenograstim
      • Pegfilgrastim
  • Treatment Type
    • Curative Therapy
    • Prophylactic Therapy
  • Route of Administration
    • Injectable
    • Oral
  • End-Use
    • Hospitals
    • Research and Academic Institutes
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer leading to higher chemotherapy usage and subsequent rise in cases of induced neutropenia
5.1.1.2. Growing awareness and early diagnosis of chemotherapy-induced neutropenia enhancing patient management strategies
5.1.1.3. Advancements in supportive care therapies and growth factors to effectively mitigate neutropenia risks
5.1.1.4. Government and healthcare initiatives promoting research and development of novel treatments for chemotherapy-induced neutropenia
5.1.2. Restraints
5.1.2.1. Lack of awareness and education among patients and healthcare providers regarding neutropenia risks and treatment options in chemotherapy
5.1.2.2. High treatment costs and limited reimbursement options hindering patient access to chemotherapy induced neutropenia therapies
5.1.3. Opportunities
5.1.3.1. Innovative combination therapies integrating immunotherapy and g-csf in chemotherapy induced neutropenia management
5.1.3.2. Personalized medicine approaches using genetic screening to tailor treatments for neutropenia caused by chemotherapy
5.1.3.3. Expansion of telehealth services for remote monitoring and management of neutropenic patients undergoing chemotherapy
5.1.4. Challenges
5.1.4.1. Economic and healthcare policy challenges impacting chemotherapy induced neutropenia market dynamics
5.1.4.2. Technological and infrastructure limitations hindering advancements in chemotherapy induced neutropenia management
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Chemotherapy Induced Neutropenia Market, by Type of Drug
6.1. Introduction
6.2. Antibiotics
6.3. Antifungals
6.4. Antivirals
6.5. Colony Stimulating Factor
6.5.1. Filgrastim
6.5.2. Lenograstim
6.5.3. Pegfilgrastim
7. Chemotherapy Induced Neutropenia Market, by Treatment Type
7.1. Introduction
7.2. Curative Therapy
7.3. Prophylactic Therapy
8. Chemotherapy Induced Neutropenia Market, by Route of Administration
8.1. Introduction
8.2. Injectable
8.3. Oral
9. Chemotherapy Induced Neutropenia Market, by End-Use
9.1. Introduction
9.2. Hospitals
9.3. Research and Academic Institutes
9.4. Specialty Clinics
10. Americas Chemotherapy Induced Neutropenia Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Chemotherapy Induced Neutropenia Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Chemotherapy Induced Neutropenia Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET RESEARCH PROCESS
FIGURE 2. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET DYNAMICS
TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LENOGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CURATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLACTIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 42. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 43. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 44. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 45. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 47. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 48. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 49. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 50. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 69. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 70. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 71. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 74. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 75. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 76. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 84. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 85. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 86. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 87. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 114. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 115. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 116. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 117. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 130. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 131. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 132. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 135. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 136. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 137. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 140. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 141. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 142. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 143. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 145. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 146. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 147. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 150. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 151. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 152. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 153. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 160. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 161. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 162. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 175. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 176. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 177. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 180. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 181. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 182. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 185. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 186. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 187. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 205. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 206. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 207. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 220. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 221. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 222. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 235. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SHARE, BY KEY PLAYER, 2023
TABLE 236. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Chemotherapy Induced Neutropenia market, which are profiled in this report, include:
  • Amgen Inc.
  • Apotex Inc.
  • Baxter International Inc.
  • BeyondSpring Pharmaceuticals
  • Biogen Inc.
  • Coherus BioSciences
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • G1 Therapeutics
  • Hoffmann-La Roche Ltd.
  • Kiadis Pharma
  • Mylan N.V.
  • Novartis AG
  • OncoGenerix USA Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 7.77 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.87 Billion
Compound Annual Growth Rate4.2%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report - Product Image

Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report

  • Report
  • 381 Pages
  • Global
From
Chemotherapy-Induced Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Chemotherapy-Induced Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 138 Pages
  • Global
From
Chemotherapy Induced Neutropenia Market Report and Forecast 2024-2032 - Product Image

Chemotherapy Induced Neutropenia Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • Global
From
Chemotherapy Induced Febrile Neutropenia - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chemotherapy Induced Febrile Neutropenia - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Chemotherapy Induced Neutropenia - Pipeline Insight, 2024 - Product Image

Chemotherapy Induced Neutropenia - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Chemotherapy Induced Neutropenia Market

In the context of healthcare services, the chemotherapy-induced neutropenia (CIN) market encompasses the range of medical treatments, products, and services used to prevent and manage neutropenia, a common side effect of chemotherapy where a patient's neutrophil count becomes abnormally low, increasing the risk of infection. The market includes pharmaceuticals such as colony-stimulating factors (CSFs), which stimulate the bone marrow to produce more white blood cells, antibiotics for the prevention and treatment of infections, and diagnostic services that monitor neutrophil counts and infection markers. Healthcare service providers such as hospitals, specialty clinics, and oncology centers play a crucial role in administering these treatments and monitoring patient health outcomes. Research and development efforts in this market aim to deliver more efficacious and safer therapies, with a focus on personalized medicine approaches that tailor treatment to individual patient needs and genetic profiles. Companies operating within the CIN market span a variety of pharmaceutical manufacturers and biotechnology firms. Some notable players include Amgen, which produces Neupogen and Neulasta, drugs that are commonly used to treat neutropenia, and Pfizer, which offers a biosimilar to Neulasta called Nivestym. Other companies involved in the production of treatments for CIN include Teva Pharmaceutical Industries, Novartis, and Mylan, which offer generic and biosimilar versions of CSFs and supportive care medications essential for managing neutropenia in chemotherapy patients. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.